Jeffrey Kindler - Perrigo Independent Director

PRGO
 Stock
  

USD 40.57  0.40  0.98%   

  Director
Mr. Jeffrey B. Kindler serves as Independent Director of the Company. Mr. Kindler was a Venture Partner at Lux Capital, a VC firm, since 2012, and has served as CEO of Centrexion Corporationrationration, a privately held bio therapeutics company that develops pain therapies, since 2013. In addition, Mr. Kindler serves as Executive Chairman of vTv, Managing Director at Starboard Capital Partners, and advisor to a number of healthcare companies. Prior to this, Mr. Kindler was Chairman and CEO of Pfizer, Vice President of Litigation and Legal Policy at General Electric Company, Executive Vice President and General Counsel at McDonalds, and President at Partner Brands. In addition, Mr. Kindler has served as a director of Intrexon since 2011, also serving as Chair of the Audit Committee, vTv Therapeutics since 2015, and Siga Technologies since 2013, as well as a number of privately held companies.
Age: 64  Director Since 2017      
353 1 709 4000  https://www.perrigo.com

Perrigo Management Efficiency

Perrigo Company has return on total asset (ROA) of 1.05 % which means that it generated profit of $1.05 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (2.42) %, meaning that it created substantial loss on money invested by shareholders. Perrigo management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 3.69 B in liabilities with Debt to Equity (D/E) ratio of 0.72, which is about average as compared to similar companies. Perrigo Company has a current ratio of 2.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Perrigo until it has trouble settling it off, either with new capital or with free cash flow. So, Perrigo's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Perrigo Company sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Perrigo to invest in growth at high rates of return. When we think about Perrigo's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing few of many executives

DIRECTOR Since

Eric AguiarBiohaven Pharmaceutical Holding
2017
Robert HuginBiohaven Pharmaceutical Holding
2020
William BrodyInternational Business Machines
2007
Thomas MayBank Of America
2004
Bob TepperAllena Pharmaceuticals
N/A
Dan LittmanPfizer Inc
2018
John CoganGilead Sciences
2013
Michael BrownRegeneron Pharmaceuticals
1991
Felix BakerSeagen Inc
2005
John MadiganGilead Sciences
2005
Peter VoserInternational Business Machines
2015
Stacy SmithIntel Corp
2016
Risa LavizzoMoureyIntel Corp
2018
Huda ZoghbiRegeneron Pharmaceuticals
2016
Alfred GilmanRegeneron Pharmaceuticals
1990
TsuJae LiuIntel Corp
2016
Per WoldOlsenGilead Sciences
2010
Linda HudsonBank Of America
2012
Thomas BuberlInternational Business Machines
2020
Nancy SimonianSeagen Inc
2012
Daniel WelchSeagen Inc
2007
Perrigo Company plc provides over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. Perrigo operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 9900 people. Perrigo Company (PRGO) is traded on New York Stock Exchange in USA and employs 9,900 people.

Perrigo Company Leadership Team

Elected by the shareholders, the Perrigo's board of directors comprises two types of representatives: Perrigo inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Perrigo. The board's role is to monitor Perrigo's management team and ensure that shareholders' interests are well served. Perrigo's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Perrigo's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Hendrickson, President
Gary Cohen, Independent Director
Arthur Shannon, IR Contact Officer
Svend Andersen, Executive Vice President and President - Consumer Healthcare International
Judy Brown, CFO and Executive VP
Laurie Brlas, Independent Director
Donal OConnor, Independent Director
James Michaud, Chief Human Resource Officer, Executive Vice President
Theodore Samuelsto, Independent Director
Scott Jamison, Executive Vice President General Manager - Nutritionals
Ellen Hoffing, Independent Director
Marc Coucke, Executive Vice President General Manager - Omega Pharma Business
Thomas Farrington, Executive Vice President, Chief Information Officer
Jeffrey Needham, Executive Vice President General Manager - Consumer Healthcare
Todd Kingma, Executive Vice President, General Counsel, Company Secretary
Rolf Classon, Independent Chairman of the Board
Raymond Silcock, Chief Financial Officer, Executive Vice President
Shlomo Yanai, Independent Director Nominee
Michael Stewart, Senior Vice President - Global Human Resources
Jeffrey Kindler, Independent Director
Jacqualyn Fouse, Independent Director
Grainne Quinn, Executive Vice President Chief Medical Officer
Murray Kessler, President, Chief Executive Officer, Director
Erica Mann, Independent Director
Richard Sorota, Executive Vice President, General Manager - of Consumer Self-Care Americas
Gary Kunkle, Lead Independent Director
Katherine Doyle, Independent Director
Joseph Papa, Chairman and CEO
Bradley Alford, Independent Director
Jeffrey Smith, Independent Director
James Dillard, Executive Vice President, President - Consumer Self-Care Americas
Douglas Boothe, Executive Vice President General Manager - Rx Pharmaceuticals
Orlando Ashford, Independent Director
Ronald Winowiecki, Acting CFO
Louis Yu, Executive Vice President - Global Quality
John Wesolowski, Executive Vice President and Presidentident - RX
Adriana Karaboutis, Independent Director
Michael Jandernoa, Independent Director
Paul Weninger, Executive Vice President - Global Quality Operations
Herman Morris, Independent Director
Jatin Shah, Senior Vice President Chief Scientific Officer
Robert Willis, Chief Human Resource Officer, Executive Vice President
Theodore Samuels, Independent Director
Geoffrey Parker, Independent Director
Sharon Kochan, Executive Vice President, President - RX Pharmaceuticals
Marry Brlas, Independent Chairman of the Board
Bradley Joseph, IR Contact Officer
Ronald Janish, Executive Vice President - Global Operations and Supply Chain, Chief Transformation Officer
Uwe Rohrhoff, President CEO, Director

Perrigo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Perrigo a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Perrigo without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Directory Now

   

Bond Directory

Find actively traded corporate debentures issued by US companies
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check Your Equity Center. Note that the Perrigo Company information on this page should be used as a complementary analysis to other Perrigo's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Perrigo Stock analysis

When running Perrigo Company price analysis, check to measure Perrigo's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perrigo is operating at the current time. Most of Perrigo's value examination focuses on studying past and present price action to predict the probability of Perrigo's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Perrigo's price. Additionally, you may evaluate how the addition of Perrigo to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Is Perrigo's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Perrigo. If investors know Perrigo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Perrigo listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.64
Market Capitalization
5.6 B
Quarterly Revenue Growth YOY
0.064
Return On Assets
0.0089
Return On Equity
-0.0253
The market value of Perrigo Company is measured differently than its book value, which is the value of Perrigo that is recorded on the company's balance sheet. Investors also form their own opinion of Perrigo's value that differs from its market value or its book value, called intrinsic value, which is Perrigo's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Perrigo's market value can be influenced by many factors that don't directly affect Perrigo's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Perrigo's value and its price as these two are different measures arrived at by different means. Investors typically determine Perrigo value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Perrigo's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.